Healthcare Industry News:  Misonix 

Devices Distribution

 News Release - September 17, 2007

Misonix Extends Contract with Mentor Corporation with Plans to Increase Share of Ultrasound Assisted Liposuction Market

FARMINGDALE, N.Y.--(HSMN NewsFeed)--Misonix, Inc. (Nasdaq: MSON ), a developer of ultrasonic medical device technology for the treatment of cancer and other chronic health conditions, announced today that it has extended its agreement with the Mentor Corporation (NYSE: MNT ) for domestic sales of its ultrasound assisted liposuction ("UAL") product, the LySonix® 3000. Under the terms of the new contract, Mentor has agreed to minimum purchase order provisions for the LySonix 3000 for a term of one year, beginning September 30, 2007, and successive annual renewals upon mutual agreement by the companies.


In connection with the distribution agreement, Mentor's promotional efforts will include a re-launch of the UltraSculpt(TM) marketing platform, which maintains a presence on Mentor's website, trade journal advertisements, the production of physician/patient marketing collateral, and training workshops. In addition, the companies will collaborate on new product development targeting product line extensions and new aesthetic applications.

"Misonix is a proven leader in the development of best-in-class ultrasonic medical devices and we are excited to have renewed our partnership for the distribution of the LySonix 3000," commented Joshua H. Levine, President and Chief Executive Officer. "Mentor and Misonix have for five years jointly pursued the aesthetic market with an ultrasonic assisted liposuction device that has consistently been a leader in its segment. We intend to build on this relationship and harness the potential for market expansion."

"We are very pleased to extend our agreement with Mentor, a major force in the aesthetic surgery market," said Michael A. McManus, Jr, Chief Executive Office of Misonix. "We look forward to working with Mentor to grow the UAL market and expand the potential applications for this valuable surgical tool."

Liposuction is one of the major product segments of the $12 billion aesthetic procedure market, with the number of procedures reaching over 400,000 last year alone, according to the American Society of Plastic Surgeons. UAL provides multiple benefits to both the patient and surgeon, including smaller incision sites, targeted fat removal, less bleeding and bruising, faster procedure time and reduced physician fatigue.

About Mentor Corporation:

Founded in 1969, Mentor Corporation is a leading supplier of medical products for the global aesthetic market. The Company develops, manufactures and markets innovative, science-based products for surgical and non-surgical medical procedures that allow patients to retain a more youthful appearance and improve personal well-being. The Company's website is www.mentorcorp.com.

About Misonix:

Misonix, Inc. (NASDAQ: MSON ) designs, develops, manufactures, and markets medical, scientific, and industrial ultrasonic equipment, laboratory safety equipment, and air pollution control products. Misonix's ultrasonic platform is the basis for several innovative medical technologies. Misonix has a minority equity position in Focus Surgery, Inc. which uses high intensity focused ultrasound technology to destroy deep-seated cancerous tissues without affecting surrounding healthy tissue. Addressing a combined market estimated to be in excess of $3 billion annually, Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.Misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.


Source: Misonix

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.